——————
参考文献:
[1] Shi Y, Au JS, Thongprasert S, Srinivasan S, Tsai CM, Khoa MT, et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER) J Thorac Oncol. 2014;9:154–62.
[2] Lai Y, Zhang Z, Li J, Sun D, Zhou Y, Jiang T, et al. EGFR mutations in surgically resected fresh specimens from 697 consecutive Chinese patients with non-small cell lung cancer and their relationships with clinical features. Int J Mol Sci. 2013;14:24549–59.
[3] Tanaka K, Nosaki K, Otsubo K, et al. Acquisition of the T790M resistance mutation during afatinib treatment in EGFR tyrosine kinase inhibitor-naïve patients with non-small cell lung cancer harboring EGFR mutations. Oncotarget. 2017;8(40):68123–68130. Published 2017 Jul 12. doi:10.18632/oncotarget.19243
[4] Soria, Jean-Charles & Ohe, Yuichiro & Vansteenkiste, Johan & Reungwetwattana, Thanyanan & Chewaskulyong, Busyamas & Lee, Ki Hyeong & Dechaphunkul, Arunee & Imamura, Fumio & Nogami, Naoyuki & Kurata, Takayasu & Okamoto, Isamu & Zhou, Caicun & Chul Cho, Byoung & Cheng, Ying & Kyung Cho, Eun & Jye Voon, Pei & Planchard, David & Su, Wu-Chou & E. Gray, Jhanelle & S. Ramalingam, Suresh. (2017). Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer. New England Journal of Medicine. 378. 10.1056/NEJMoa1713137.
[5] Suresh S Ramalingam, et al. 2018 ESMO. MECHANISMS OF ACQUIRED RESISTANCE TO FIRST-LINE OSIMERTINIB: PRELIMINARY DATA FROM THE PHASE III FLAURA STUDY
[6] Oxnard G R, Hu Y, Mileham K F, et al. Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M–Positive Lung Cancer and Acquired Resistance to Osimertinib[J]. JAMA Oncology, 2018, 4(11): 1527-1534. doi:10.1001/jamaoncol.2018.2969
[7] https://oncologypro./Meeting-Resources/ESMO-2018-Congress/Which-is-better-EGFR-TKI-followed-by-osimertinib-between-afatinib-and-gefitinib-erlotinib
[8] Hochmair, Maximilian & Morabito, Alessandro & Hao, Desiree & Yang, Cheng-Ta & A Soo, Ross & Yang, James Chih-Hsin & Gucalp, Rasim & Halmos, Balazs & Wang, Lara & Golembesky, Amanda & Märten, Angela & Cufer, Tanja. (2018). Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: An observational study. Future Oncology. 14. 10.2217/fon-2018-0711.
[9] www.boehringer-ingelheim.com/press-release/giotagsequencingresults
[10] Halmos, Balazs & Tan, Eng-Huat & A. Soo, Ross & Cadranel, Jacques & Ki Lee, Min & Foucher, Pascal & Hsia, Te-Chun & Hochmair, Maximilian & Griesinger, Frank & Hida, Toyoaki & Kim, Edward & Melosky, Barbara & Märten, Angela & Carcereny, Enric. (2018). Impact of Afatinib Dose Modification on Safety and Effectiveness in Patients with EGFR Mutation-Positive Advanced NSCLC: Results from a Global Real-World Study (RealGiDo). Lung Cancer. 127. 10.1016/j.lungcan.2018.10.028.